A. Hackshaw

Publications285
h-index49
Citations10,914
Highly Influential Citations357
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Wardle
  • 826 Publications, 56,531 Citations
  • C. von Wagner
  • 142 Publications, 3,882 Citations
  • J. Wolchok
  • 671 Publications, 89,078 Citations
  • N. McGranahan
  • 100 Publications, 11,842 Citations
  • Publications
  • Influence
Tracking the Evolution of Non‐Small‐Cell Lung Cancer
BACKGROUND Among patients with non‐small‐cell lung cancer (NSCLC), data on intratumor heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. We wanted to… Expand
  • 844
  • 36
  • PDF
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
BACKGROUND It is not known whether low-dose radioiodine (1.1 GBq [30 mCi]) is as effective as high-dose radioiodine (3.7 GBq [100 mCi]) for treating patients with differentiated thyroid cancer or… Expand
  • 431
  • 23
Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls
BACKGROUND There is uncertainty over whether maternal smoking is associated with birth defects. We conducted the first ever comprehensive systematic review to establish which specific malformations… Expand
  • 450
  • 18
  • PDF
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic… Expand
  • 523
  • 15
  • PDF
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer
Background The prognosis for patients with hepatocellular cancer (HCC) undergoing transarterial therapy (TACE/TAE) is variable. Methods We carried out Cox regression analysis of prognostic factors… Expand
  • 161
  • 14
  • PDF
Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme
would have been much lower (51%, 95% CI 41–62%), the false-positive rate more than twice as high (14%), and the odds of being affected in those with a positive result less favourable (1:147) than… Expand
  • 83
  • 11
European Code Against Cancer and scientific justification: third version (2003).
P. Boyle*, P. Autier, H. Bartelink, J. Baselga, P. Boffetta, J. Burn, H. J. G. Burns, L. Christensen, L. Denis, M. Dicato, V. Diehl, R. Doll, S. Franceschi, C. R. Gillis, N. Gray, L. Griciute, A.… Expand
  • 312
  • 10
Antenatal screening for Down's syndrome.
BACKGROUND In 1968 the first antenatal diagnosis of Down's syndrome was made and screening on the basis of selecting women of advanced maternal age for amniocentesis was gradually introduced into… Expand
  • 215
  • 10
Tobacco smoke and involuntary smoking.
  • 1,428
  • 9
First-trimester or second-trimester screening, or both, for down's syndrome
background It is uncertain how best to screen pregnant women for the presence of fetal Down’s syndrome: to perform first-trimester screening, to perform second-trimester screening, or to use… Expand
  • 471
  • 9